stockmarketproxy
/
CGONNasdaq SEC EDGAR

CG Oncology, Inc.

Biological Products, (No Diagnostic Substances)·DALLAS, TX·FY end 12/31·CIK 1991792
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

2-year history · USD
MetricFY 2025FY 2024Trend
Revenue———
Gross Profit———
Operating Income-$190.8M-$114.7M
Net Income-$161.0M-$88.0M
Operating CF-$132.3M-$78.7M
Capex$134.0K$234.0K
Free Cash Flow-$132.5M-$78.9M
Buybacks———
Dividends———
Gross Margin———
Operating Margin———
Net Margin———
FCF Margin———
R&D / Revenue———
Effective Tax———
Debt / Equity0.00——
Buybacks / FCF———

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
CGON
6:1
EXEL
81:1
GILD
119:1
BIIB
113:1
PCVX
48:1
IBRX
69:1
CEO total comp
CGON
$12M
EXEL
$33M
GILD
$28M
BIIB
$24M
PCVX
$14M
IBRX
$13M
Net Margin
CGON
—
EXEL
33.7%
GILD
28.9%
BIIB
13.1%
PCVX
—
IBRX
-310.2%